February 01, 2020
1 min read

Hematology scholars to participate in ASH faculty development program

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Gabriela S. Hobbs, MD 
Gabriela S. Hobbs
Oluwatoyosi Adefunke Onwuemene, MD, MS 
Oluwatoyosi Adefunke Onwuemene

Gabriela S. Hobbs, MD, and Oluwatoyosi Adefunke Onwuemene, MD, MS, will participate in the American Society of Hematology-Harold Amos Medical Faculty Development Program.

The program, a partnership between ASH and Robert Wood Johnson Foundation, is intended to increase the number of underrepresented minority scholars in hematology with academic and research appointments.

The program provides 4-year research awards that total $420,000. Participants spend at least 70% of their research time under mentorship of a senior faculty member at their institution.

Hobbs is assistant professor of medicine at Massachusetts General Hospital Cancer Center and a HemOnc Today Next Gen Innovator. Her research focuses on integrating molecular genetics into clinical decision-making to improve outcomes for patients with myelofibrosis who undergo allogeneic stem cell transplant.

Onwuemene is assistant professor of medicine-hematology at Duke University. Her research focuses on developing apheresis-specific outcomes to facilitate a multicenter study of therapeutic plasma exchange in heparin-induced thrombocytopenia.

“Drs. Hobbs and Onwuemene are two dedicated physician investigators who are addressing critical research questions in their respective fields,” ASH President Stephanie Lee, MD, MPH, associate director of the clinical research division and chair of cancer research at Fred Hutchinson Cancer Research Center, said in a press release. “The society is pleased to support such promising young investigators who will be part of the next generation to propel the science and practice of hematology forward.”